George D Demetri MD

Hematologic Oncology, Melanoma, Sarcoma

Professor of Medicine, Harvard Medical School and Director, Ludwig Center at Harvard; Director, Sarcoma Center, Dana-Farber/Brigham and Women's Cancer Center

Join to View Full Profile

450 Brookline AveDana-Farber Cancer InstituteBoston, MA 02215
Phone+1 617-632-5204
Fax+1 617-632-3408

Summary

Dr. George Demetri is an oncologist in Boston, MA and is affiliated with multiple hospitals affiliated with Harvard Medical School in the area, primarily the Dana-Farber Cancer Institute. He received his medical degree from Stanford University School of Medicine and has been in practice 34 years. He specializes in Sarcomas and Developmental Therapeutics
.

Education & Training

Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1985 - 1989
University of WashingtonResidency, Internal Medicine, 1983 - 1985
Stanford University School of MedicineClass of 1983

Certifications & Licensure

FL State Medical License 2022 - Present
MA State Medical License 1986 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Fellow (FASCO) American Society of Clinical Oncologists, 2008
Super Doctor SuperDoctors.com
Whos Who in Medicine and Healthcare Marquis Whos Who

Clinical Trials

Troglitazone in Treating Patients With Liposarcoma Start of enrollment: 1997 Jun 01
Completed
Phase 2
Bexarotene in Treating Patients With Metastatic Breast Cancer Start of enrollment: 1998 Oct 01
Completed
Phase 2
Rosiglitazone in Treating Patients With Liposarcoma Start of enrollment: 1999 Oct 01
Completed
Phase 2
SU5416 in Treating Patients With Advanced, Metastatic, or Recurrent Soft Tissue Sarcomas Start of enrollment: 2000 Oct 01
Completed
Phase 2
Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor Start of enrollment: 2000 Dec 01
Terminated
Phase 3
Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans Start of enrollment: 2004 May 01
Completed
Phase 2
Trastuzumab in Treating Patients With Locally Advanced or Metastatic Synovial Sarcoma Start of enrollment: 2005 Jul 01
Completed
Phase 2
S0423 Pemetrexed Disodium in Treating Patients With Recurrent and Unresectable or Metastatic Chondrosarcoma Start of enrollment: 2005 Sep 01
Completed
Phase 2
S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas Start of enrollment: 2006 Mar 01
Completed
Phase 2
Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS) Start of enrollment: 2005 Dec 01
Completed
Phase 1
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor Start of enrollment: 2008 Apr 01
Terminated
Phase 3
Study of an Experimental New Drug, PPARγ Agonist Taken by Mouth by Participants With Advanced or Metastatic Cancer Start of enrollment: 2006 Nov 01
Completed
Phase 1
Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib Start of enrollment: 2008 Aug 01
Terminated
Phase 3
A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST
COMPLETED
PHASE2
A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors Start of enrollment: 2013 Mar 20
Completed
Phase 1
BKM120 for Patients With PI3K-activated Tumors Start of enrollment: 2013 Mar 29
Completed
Phase 2
Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma Start of enrollment: 2013 Jul 01
Active, not recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

SaLudo: a randomized phase IIb/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcoma.
Gregory M Cote, Sant P Chawla, George Demetri, Bernd Kasper, Robin L Jones
Future Oncology. 2025-04-01
Epigenetic dysregulation of metabolic programs mediates liposarcoma cell plasticity.
Erica M Pimenta, Amanda E Garza, Sabrina Y Camp, Jihye Park, Samantha E Hoffman
Biorxiv. 2025-01-24
2 citations
Improving Collection and Analysis of Overall Survival Data.
Lisa R Rodriguez, Nicole J Gormley, Ruixiao Lu, Anup K Amatya, George D Demetri
Clinical Cancer Research. 2024-09-13

Lectures

First-in-human phase 1 study of ABBV-085, an antibody-drug conjugate (ADC) targeting LRRC15, in sarcomas and other advanced solid tumors.
2019 ASCO Annual Meeting - 6/1/2019

Other

Adjuvant and neoadjuvant imatinib for gastrointestinal stromal tumors
Demetri GD, Raut CP, Morgan J
http://www.uptodate.com/contents/adjuvant-and-neoadjuvant-imatinib-for-gastrointestinal-stromal-tumo
UpToDate, Wolters Kluwer Health - 2013-01-15
Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST
Demetri GD, Raut CP, Morgan J
http://www.uptodate.com/contents/epidemiology-classification-clinical-presentation-prognostic-featur
UpToDate, Wolters Kluwer Health - 2013-02-04
Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract
Demetri GD, Raut CP, Morgan J
http://www.uptodate.com/contents/local-treatment-for-gastrointestinal-stromal-tumors-leiomyomas-and-
UpToDate, Wolters Kluwer Health - 2013-01-16
Surgical treatment and other localized therapy for metastatic soft tissue sarcoma
Demetri GD, Raut CP, George S
http://www.uptodate.com/contents/surgical-treatment-and-other-localized-therapy-for-metastatic-soft-
UpToDate, Wolters Kluwer Health - 2012-07-03
Systemic treatment of metastatic soft tissue sarcoma
Demetri GD, George S
http://www.uptodate.com/contents/systemic-treatment-of-metastatic-soft-tissue-sarcoma
UpToDate, Wolters Kluwer Health - 2013-03-18
Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors
Demetri GD, Morgan J
http://www.uptodate.com/contents/tyrosine-kinase-inhibitor-therapy-for-advanced-gastrointestinal-str
UpToDate, Wolters Kluwer Health - 2013-02-27
Join now to see all

Press Mentions

7 Big Questions About Cancer, AnsweredJanuary 29th, 2025
For New NCI Director, Work Turns Personal: She Is Diagnosed with CancerDecember 14th, 2022
Cancer Combination Therapy Company IDRx Launches with $122M Series a FundingAugust 2nd, 2022
Join now to see all